It is plausible that triple combined blockade of GPX4, ALK, and activated bypass signals may be a potent therapeutic strategy for patients with ALK+ NSCLC to prevent the development of drug resistance, and lead to tumor eradication. This evidence concerns the gene GPX4 and non-small cell lung carcinoma.